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1

Introduction:
There were an estimated 527,600 new cervical cancer cases and 265,700 deaths from

cervical cancer worldwide in 2012 (Torre et al., 2015). Until recently the primary method for
cervical screening was based on the Papanicolaou test (Pap test). The Pap test requires cells to
be scraped from the cervix, fixed to a glass slide, stained and reviewed by a trained cytologist.
Cellular abnormalities are identified by the cytologist based on cellular morphology and
staining characteristics and classified according to the degree of dysplasia (Low grade or High
grade). The advantage of the Pap test is that it is a non-invasive and widely accepted screening
based test with a high specificity of 95-98% and a sensitivity of 74-96% ( Kitchener et al.,
2011). The variability in the rates of sensitivity can be due to sampling technique; the
subjectivity of the cytology based screening and can result in a high rate of gynaecological
referral and patient recall which adds to cost and patient stress. Persistent infection with high
risk human papillomavirus (HPV), such as HPV types 16, 18, is accepted as the major cause of
cervical pre-cancer and cancer (Walboomers et al., 1999)(Ronco et al., 2010). HPV DNA
testing has a higher sensitivity (>95%) but lower specificity (~ 84%) than the Pap test (Cuzick
et al., 2013) and these tests are expensive, time-consuming and provide no information on
cervical cytopathology. Current gold standard methods for detection of cervical cancer and precancer are therefore limited and there is an unmet clinical need for new objective screening or
diagnostic tests. Optical spectroscopic techniques, such as Raman or infrared spectroscopy, are
label-free, non-invasive and have several advantages over traditional approaches, including
objectivity, speed and cost. These methods can provide quantitative information based on the
spectroscopic signature of the biochemical components of the sample allowing diagnosis to be
based on biochemical changes rather than on morphological changes. The focus of the present
study is on Raman spectroscopy which is based on inelastic light scattering. The coupling of
the light generates vibrations within the material and these vibrations are characteristic of the

chemical structure, the energy of the scattered light is reduced by an amount equal to the
vibrational energy and from this a rapid, label free, non-destructive measurement of the
complete biochemical fingerprint of a biological sample can be obtained. Over the past
15 years, the potential of Raman spectroscopy together with multivariate statistical analysis
has been demonstrated for the detection of a variety of cancers, including cervical cancer (Diem
et al., 2013) (Lyng et al., 2015) In initial infrared spectroscopy studies on cervical
cytopathology samples (González-Solís et al., 2014)(González-Solís et al., 2013)(Wong et al.,
1991), spectra were recorded from cell pellets rather than from single cells and the presence of
metaplastic cells, endocervical columnar cells, polymorphs, blood, cervical mucus and debris
were all identified as confounding factors (Wong et al, 2002)(Chiriboga et al.,
1998)(Cohenford et al., 1997)(Diem et al., 2002) (Romeo et al., 2003) (Wood et al., 1998).
Recent studies by (Ramos et al., 2016) and (Bonnier et al., 2014) addressed the variability in
Raman spectra from cervical smear samples and reported a new method to clear blood residue
contamination before Raman spectroscopy based on pre-treatment of the slides with hydrogen
peroxide. This method significantly minimised variability and resulted in the collection of
highly reproducible data and was employed in this study to reduce variability based on the
presence of blood residue. Physiological factors such as hormonal changes during the
menstrual cycle or during menopause may also be potential sources of variability in the normal
cervix.
The cellular make up of an individual woman’s smear is dependent on which day during
the menstrual cycle the sample was taken. Days 1-4 are classed as the menstruation phase of
the cycle when bleeding will occur and smear samples are generally not taken during this phase.
Days 5-13 are classified as the proliferative phase. During this phase oestrogen levels reach
their peak resulting in complete maturation of the squamous epithelium and the cervical smear
will present with a higher ratio of superficial cells to intermediate cells. Days 14-28 are

classified as the secretory phase where progesterone production reaches its peak and prevents
complete maturation of the epithelium. The cervical smear will present with a higher ratio of
intermediate cells to superficial cells. During menopause, levels of both oestrogen and
progesterone will drop dramatically and there is a gradual arrest of the maturation of the
squamous epithelium. This results in the loss of superficial and intermediate cells leading to
the final atrophic stage where the squamous epithelium is composed entirely of parabasal cells.
The use of hormone based contraceptives (HC) will affect the natural hormone
mediated maturation process of the cervical epithelium. A study by (Romeo et al., 1998) used
infrared spectroscopy to investigate hormonal influences on cervical cells throughout the
menstrual cycle and showed spectral changes such as increases in the 1200-1000 cm-1 region
due to glycogen increases around ovulation (mid cycle). Cervical cells from women on HC
did not show the same degree of spectral changes as cells from women not on HC. Despite the
variability throughout the menstrual cycle, principal component analysis (PCA) showed good
discrimination between high grade dysplasia and normal samples collected at different phases
of the menstrual cycle.
A more recent study by (Kanter et al.,2009) has shown that hormonal differences due
to the menstrual cycle can influence the Raman spectra acquired from the cervix in vivo.
Spectra were divided into four groups, pre-menopausal proliferative phase (days 1-14), premenopausal secretory phase (day 15-28+), peri-menopausal and post-menopausal. Spectral
differences were mainly observed at 1250, 1300 and 1320 cm-1, most likely due to changes in
the proteins collagen and elastin (Movasaghi et al.,2007). Incorporating hormonal status into
their dysplasia classification algorithm increased the classification accuracy from 88% to 94%.
The main objective of our study was to investigate hormone associated changes in the
Raman spectra of cytologically negative ThinPrep cervical smear samples related to; (1) the
menstrual cycle, (2) the onset of menopause and (3) the use of hormone based contraceptives.

A further objective was to determine if any changes observed would interfere with the ability
to discriminate normal and high grade dyskaryotic cervical smear samples caused by HPV
infection.

1.1

Materials and methods

1.1.1 Sample collection and ThinPrep slide preparation
Cervical smear samples collected in PreservCyt solution were obtained from the
Cytology Department at the Coombe Women and Infants University Hospital (CWIUH),
Dublin, Ireland, after routine cytological screening had been performed. Ethical approval for
use of anonymised samples for the study was granted by the CWIUH Research Ethics
Committee (no. 28-2014). Clinical data which was recorded relating to the samples included
cytology result, date of last menstrual period, age at time of smear test and reported use of
hormonal based contraceptives. No information on smoking status was available. A total of 60
cervical smear samples, 45 confirmed as cytology negative and 15 confirmed high grade
dyskaryosis (high grade squamous intraepithelial lesion (SIL)) samples, were used for this
study.
A slide was prepared for each sample using a ThinPrep 2000 processor (Hologic Inc;
Marlborough, MA 01752). The Thin Prep processor starts by homogenizing the sample by
spinning the filter, creating shear forces in the fluid that are strong enough to disaggregate
randomly joined material, break up blood, mucus and non-diagnostic debris. The cells are then
collected onto the membrane of the filter and transferred onto a glass slide to create a circular
monolayer deposit of cells 20mm in diameter and a few microns in thickness. The slide is then
ejected automatically into a fixative bath of 95% ethanol.
The presence of blood residues on ThinPrep slides is a limiting factor that needs to be
removed in order to collect data with minimal variability. Therefore the slides were treated

with a 30% solution of H2O2 at room temperature for 3 minutes. The slides were then placed
into a 70% solution of industrial methylated spirits (IMS) for 3 minutes followed by multiple
dips into 100% IMS to remove any remaining cellular debris and H2O2. The slide was then air
dried.

1.1.2 HPV Testing
1ml of the remaining test sample was tested for HPV using the Cobas 4800 HPV test.
The Cobas 4800 test is an automated extraction and real time PCR system that is capable of
identifying 14 different high risk HPV types as well as the ability to genotype for HPV 16/18.
The Cobas 4800 test starts by first collecting 400µl of the test sample and heating it up to start
the denaturing process. The cells are then lysed by a chaotropic reagent. The lysis step releases
the HPV nucleic acids. These nucleic acids are negatively charged which bind to positively
charged magnetic glass particles, which are held in place by a magnetic plate. The nucleic acids
are then washed and separated from the glass particles, before they are amplified and detected
by RT-PCR. Sequences of approximately 200 nucleotides are targeted by primers for the PCR
reaction. The nucleotides are located within the L1 region of the HPV genome, with the master
mix containing the primers designed for 14 different high risk HPV genotypes
(16,18,31,33.35,39,45,51,52,56,58,59,66 and 68). Fluorescent oligonucleotides are then added
which can bind to the sequences within these primers during the PCR. The detection of these
fluorescent oligonucleotides will give either a positive or negative result.

1.1.3 Raman Microspectroscopy
Raman studies were performed using a Horiba Jobin Yvon XploRA system (Villeneuve
d’Ascq, France) which incorporates the Olympus microscope Bx41. As source, a 532 nm laser
of ~12 mW power was focused onto the sample using a 100X objective (MPlan, Olympus, NA
= 0.9) giving a spot size of 1-2 µm. The confocal hole was set at 100µm for all measurements,
the specified settings for confocal operation. The system was pre-calibrated to the 520.7cm-1
spectral line for silicon. The 1200 lines per mm grating was used. The backscattered light was
measured using an air cooled CCD detector (Andor, 1024-256 pixels). The spectrometer was
controlled by Labspec V5.0 software. For each cell, one spectrum was recorded from the
nucleus for 2 accumulations of 30 seconds in the spectral range of 400-1800cm-1. Spectra were
recorded only from the cell nucleus as these have been found to be more reproducible and
consistent than spectra from the cell cytoplasm. On average 30 cells were recorded from each
sample (superficial and intermediate cells). The x,y co-ordinates of each cell was recorded on
the Raman microscope. After Raman acquisition was complete and following Pap staining,
each cell could be re-visited and assigned as superficial or intermediate. The 15 high grade
dyskaryotic smears were screened for HSIL cells and spectra recorded accordingly.

Data Pre-Processing and Analysis
Data was normalised and analysed using Matlab software (Mathworks) and specific scripts
1.1.4

developed and adapted for uploading of the spectra and their pre-processing, including
smoothing (Savitzky-Golay K=5, K=13), baseline correction (Rubberband) and vector
normalization. An in house method for glass removal based on non-negativity constrained
least squares was used to remove the spectral features of glass (Kearney et al., 2017). The
algorithm weights the values of glass as well as cell components in the acquired spectra from
the cell and further subtracts the glass from the cell spectra applying non-negative constraints.
Classification methods find mathematical models that are able to recognize the membership of
each sample to its appropriate class on the basis of a set of measurements. When the
classification model has been calibrated, the membership of unknown samples to one of the
defined classes can be predicted. Although PCA-LDA is the standard method used to maximise
the variations in the X direction, PLS-DA by rotating both the X and Y axes allows even small
variations to be captured. This was necessary to identify the normal biochemical changes
associated with the menstrual cycle. Partial Least Squares Discriminant Analysis (PLS-DA)
was used to build classification models in this study together with leave-one patient-out crossvalidation. PLS-DA analysis was performed using the PLS toolbox (Eigenvector Research) in
the Matlab (Mathworks Inc.) environment.
From the data provided by the patient about their last menstrual period and the day on which
the sample was taken, the day of the menstrual cycle the smear was taken was calculated. It
was assumed that each patient follows the standard 28 day cycle. Samples were only available
from days 7-24 of the cycle. Table 2 shows the sample details including day of the menstrual
cycle, menopausal status and use of hormone based contraceptive (HC).

Cytology
Sample number

Day of cycle

Postmenopausal

Result

Contraceptive
HPV Result

1

Negative

7

/

Negative

None

2

Negative

9

/

Negative

None

3, 4, 5, 6, 7

Negative

10

/

Negative

None

8, 9

Negative

11

/

Negative

None

10, 11, 12, 13, 14

Negative

12

/

Negative

None

15, 16, 17, 18, 19, 20, 21, 22

Negative

13

/

Negative

None

23, 24

Negative

16

/

Negative

None

25, 26

Negative

20

/

Negative

None

27

Negative

21

/

Negative

None

28

Negative

24

/

Negative

None

29, 30, 31, 32, 33, 34, 35

Negative

/

Postmenopausal

Negative

/

36, 37, 38, 39, 40, 41, 42, 43,

Negative

Negative

Hormone

44, 45
46, 47, 48, 49, 50, 51, 52, 53,
54, 55, 56, 57, 58, 59, 60

/

/

High Grade

based

Contraceptive
Positive

/

/

None

Table 3.1 Sample details including day of the menstrual cycle, menopausal status and use of hormone based contraceptive

1.2 Results and Discussion
1.2.1

Proliferative and Secretory Phase and Postmenopausal Cellular Presentation on Pap
smear.
The proliferative and secretory phase presentation of a Pap smear are shown in Figure 3.1(A)
and Figure 3.1(B) respectively. A higher ratio of superficial (pink stained) to intermediate (blue
stained) cells in the proliferative phase compared to a higher ratio of intermediate (blue stained)
to superficial (pink stained) cells in secretory phase can be observed. A postmenopausal Pap
smear is shown in Figure 3.1(C). A lack of cellular material, mucus and cellular debris can be
observed which caused difficulties in recording good quality spectra.

A

B

C

Figure 3.1 (A) Proliferative phase presentation of a Pap smear. Note the higher ratio of superficial (pink stained) to
intermediate (blue stained) cells, (B) Secretory phase presentation of a Pap smear. Note the higher ratio of intermediate
(blue stained) to superficial (pink stained) cells, (C) Postmenopausal presentation of a Pap smear. Note the lack of cellular
material, mucus and cellular debris. Bar = 35 µm.

1.2.2 Raman signature of Proliferative Phase Vs Secretory Phase
The spectral data from the Pap smears was divided up according to the day of the menstrual
cycle the sample was taken on. Figure 3.2(A) shows the mean Raman spectra of cells from
days 7 to 24 of the menstrual cycle. Increases in the Amide I (1640-1650 cm-1)(see Table 1),
Phenylalanine and Tyrosine (1605-1610 cm-1) and glycogen (480 cm-1) bands over time were
observed. The latent variables (LV) scores scatter plot Figure 3.2(B) shows reasonable
separation between the proliferative phase (blue) and the secretory phase (red). Some
overlapping is observed which is most likely due to the fact that each woman will differ slightly
between the days of the menstrual cycle and the levels of oestrogen and progesterone present.
The LV1 loadings shown in Figure 3.2(C) highlight areas similar to those highlighted in the
mean Raman spectra Figure 3.2(A). The discrimination is mainly based on glycogen (480, 937,
1381, 1458 cm-1) which is more present in the secretory samples (red) due to the higher levels
of progesterone which promotes sub nuclear glycogen accumulation (Nair et al., 2010) and
proteins (CH2 def, 1450 cm-1) and Amide I (1669 cm-1) which are higher in samples collected
from the proliferative phase of the cycle. The prediction plot from the PLS-DA model Figure
3.2(D) shows reasonably good classification of menstrual cycle phase (proliferative phase or
secretory phase) with sensitivity of 83% and specificity of 86%.
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Figure 3.2 (A) Mean Raman spectra of intermediate and superficial cells from days 7 to 24. Shading denotes the standard
deviation, (B) LV scores scatter plot of Proliferative Phase, Days 7-14 (Blue) Vs Secretory Phase, Days 15-24 (Red ), (C) LV1
loadings, (D) PLS-DA prediction plot.

1.2.3 Raman signature of postmenopausal samples
Most women are generally screened for cervical cancer up until the age of 65. Between the
ages of 48-55 most women are said to be menopausal. Hence it is important to determine if Pap
smears collected from postmenopausal women will have a similar Raman signature to nonpostmenopausal women. Mucus and cellular debris present on postmenopausal samples
obscure the little cellular material that is present on the slide and make it very difficult to obtain
good spectra hence the number of spectra recorded is severely reduced and it is difficult to
draw any firm conclusions. Figure 3.3(A) shows the mean and standard deviation spectra of
the 22 postmenopausal cells recorded. Figure 3.3(B) shows good discrimination between the
two sample types. The loadings shown in Figure 3.3(C) shows that the discrimination is based
on glycogen (852, 1106, 1138 cm-1) and nucleic acids (781 cm-1) proteins (1450 cm-1) and
Amide I (1669 cm-1). Figure 3.3(D) shows the PLS-DA prediction plot which has a sensitivity
of 100% and specificity of 95%.
Atrophic samples were not available as part of this study. No firm conclusions can be drawn
from this data set except that postmenopausal samples can represent a problem for Raman
based screening based on their Pap smear presentation due to mucus, cellular debris and lack
of cellular material.
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Figure 3.3 (A) Mean Raman spectra from postmenopausal samples. Shading denotes the standard deviation, (B) LV scatter
scores plot of postmenopausal (blue) and non-menopausal (red), (C) LV1 loadings, (D) PLS-DA prediction plot

1.2.4 Raman signature associated with women on hormone based contraceptives.
The clinical details obtained indicated if the patient was on some form of hormone based
contraceptive (HC). However information on which type of contraceptive they are currently on
was not included. The aim of this part of the study was to determine if Pap smears collected
from women on HC will have a similar Raman signature to women who are not on HC. Figure
3.4(A) shows that the levels of glycogen (482 cm-1 and 855-939 cm-1) in the HC positive
samples are lower when compared to the controls. The controls were made up of the samples
collected throughout the menstrual cycle which were HC negative. Tryptophan and
Phenylalanine at peak position (1584-1605 cm-1) and Amide I at peak (1669 cm-1) are higher
in HC samples compared to the control. The lower levels of glycogen in the HC samples could
be linked to lower levels of progesterone due to its role in promoting sub-nuclear glycogen
accumulation. The same could be said for the higher levels of proteins detected (Phenylalanine,
Tryptophan, and Amide I). There is also a consistent change in the shoulder of Amide I, which
is a change in Amide I protein position and folding between HC positive and negative samples.
Overall protein synthesis may be increased due to the constant level of hormones present.
The LV scores scatter plot Figure 3.4(B) shows good separation between HC positive
samples and HC negative samples. There is a small amount of overlapping which could be due
to a number of factors. Multiple types of contraceptive are available which contain different
types and levels of hormones, including implants, injectable contraceptive, progesterone pills,
oestrogen and progesterone pills, combined oral and the patch all of which work by maintaining
a constant level of hormones in the body thus preventing the rise and fall of oestrogen and
progesterone. Hence they may work differently and individual patients will also respond
differently to the levels of hormones present. The loadings 3.4(C) from LV1 show that
glycogen (483 and 1386 cm-1) and proteins and lipids (1146, 1450, 1566 cm-1) and Amide I
(1669 cm-1) are the main discriminating factors between HC positive and HC negative samples

The PLS-DA prediction plot Figure 3.4(D) shows excellent classification with a sensitivity of
100% and specificity of 100%.
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Figure 3.4 (A) Mean Raman spectra from HC positive and HC negative cells. Shading denotes the standard deviation, (B) LV
scatter scores plot of HC negative (blue) and HC positive (red), (C) LV1 loadings, (D) PLS-DA prediction plot.

1.2.5 Phase of Menstrual Cycle vs High Grade Dyskaryosis
It is important to determine if the changes observed throughout the menstrual cycle as seen in
Figure 3.2(A) would affect the ability of Raman spectroscopy to discriminate HSIL from
normal cells affected by the normal maturation of the cervical epithelium controlled by both
the rise and fall of progesterone and oestrogen. For this part of the study, spectra from HSIL
cells Figure 3.5(A) were recorded from 15 HPV positive, high grade dyskaryotic samples and
compared to an equivalent number of spectra from negative samples from days 7-21 of the
menstrual cycle, all of which were HPV negative. Figure 3.5(B) shows the mean spectra from
negative samples from days 7-21 of the menstrual cycle and spectra recorded from HSIL cells.
The LV scores scatterplot in Figure 3.5(C) shows that HSIL cells separate well from normal
cells on the first LV. This shows that regardless of when a sample is taken during day 7-21 of
the menstrual cycle, HSIL cells can still be effectively discriminated from cytology negative
cells using Raman spectroscopy. Spectral changes due to the hormonal influence of oestrogen
and progesterone seem to be less than the spectral changes due to the biochemical changes in
the dyskaryotic cells. The loadings from LV1 in Figure 3.5(D) show that glycogen (495, 1080,
1120, 1380, 1458 cm-1), nucleic acids (780 and 1487 cm-1), Amide III and Amide I proteins
(1239 cm-1 and 1669 cm-1 respectively) and tryptophan and phenylalanine (1605 cm-1) mainly
contribute towards the discrimination between normal and HSIL cells. As the HSIL cells are a
result of a high risk HPV infection, the biochemical difference in glycogen, proteins and
nucleic acids can be attributed to the downstream effects of the HPV infection. The predictions
plot Figure 3.5(E) from the PLS-DA model shows excellent classification of the negative
samples (all menstrual cycle phases) and the dyskaryotic samples with sensitivitiy of 98% and
a specificity of 97%.
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Figure 3.5 (A) Pap stained HSIL cells. Bar = 35 µm, (B) Mean Raman spectra from negative samples from days 7-21 of the
menstrual cycle (red) and spectra from HSIL positive samples (blue). Shading denotes the standard deviation, (C) LV scores
scatter plot of HSIL positive samples (red) and negative samples (blue), (D) LV1 loadings, (E) PLS-DA prediction plot.

1.2.6 HC positive samples vs High Grade Dyskaryosis
It is important to determine if the use of HC will also affect the ability of Raman spectroscopy
to discriminate normal HC positive cells from HSIL cells. Figure 3.6(A) shows the mean
Raman spectra of HC positive negative samples and spectra from HSIL cells. The LV scores
scatterplot in Figure 3.6(B) shows that spectra from HC positive samples separate from spectra
from HSIL cells from high grade dyskaryotic samples on the first LV component with minimal
overlap. Figure 3.6(C) shows the LV1 loadings which indicate that the main differences
between the HC positive cells and HSIL cells are very similar to those found for the HC
negative and high grade dyskaryotic samples. Glycogen (482, 1261 and 1381 cm-1), nucleic
acids (781 cm-1), and proteins (1450, 1560 and 1669 cm-1) again contribute towards the
discrimination. As before, it appears that the overtaking of the host cell machinery by HPV
causes more of a biochemical change within the cell than the biochemical changes associated
with the use of HC. The predictions plot from the PLS-DA model shows excellent classification
of the negative samples (HC positive) and the HSIL cells from high grade dyskaryotic samples
Figure 3.6(D) with sensitivity of 96% and specificity of 98%.
(Kanter et al., 2009) showed that hormonal status influences Raman spectra from the cervix in
vivo and that incorporating hormonal status into their classification algorithm increased the
accuracy from 88% to 94%. However, the present study and that of (Romeo et al., 2003) on
exfoliated cervical cells showed good discrimination between normal and abnormal samples
regardless of phase of the menstrual cycle and of whether the woman was taking oral
contraceptives or not.
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Figure 3.6 (A) Mean Raman spectra from negative HC positive samples (red) and spectra from HSIL cells (blue). Shading
denotes the standard deviation, (B) LV scores scatter plot of HSIL samples (red) and negative HC positive samples (blue), (C)
LV1 loadings, (D) PLS-DA prediction plot.

1.3 Conclusion
This study has shown that the day a Pap smear is taken during days 7-21 of the
menstrual cycle will have an effect on the spectra with regard to the level of glycogen and
proteins. It should be noted, however, that this study assumes that each patient recruited follows
the standard 28 day cycle, and that the patient details recorded for each sample were correct. It
is possible for women have a longer or shorter cycle, hence this variation may have influenced
our analysis. Postmenopausal samples represent a problem for Raman based screening due to
their lack of cellular material and presence of cellular debris and mucus. The use of HC causes
the most variability. Further study would be required to determine which hormone is causing
the discrimination between HC positive and HC negative samples. These findings suggest that
the use of oral contraceptives and the day on which the Pap smear was taken during the
menstrual cycle should be incorporated into the data analysis to reduce variability between
patient samples.
Despite this, however, the variability between days of the menstrual cycle or use of HC
did not hinder the ability of Raman spectroscopy to discriminate cytology negative cells from
HSIL cells. The biochemical changes induced in HSIL cells due to an active HPV infection

were more pronounced than the biochemical changes due to the menstrual cycle or the use of
hormone based contraceptives. It is acknowledged that the study is limited in focussing only
on HSIL positive samples and a further study would be required to include low grade (LSIL)
samples. In conclusion, this study highlights the scope of Raman spectroscopy for cervical
screening despite the presence of biochemical changes associated with the menstrual cycle and
the use of HC.
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